NOC - Northrop Grumman Corp
Executive Summary
Northrop Grumman Corporation is a leading United States prime contractor in the Aerospace & Defence sector, operating across four principal businesses - Aeronautics Systems, Mission Systems, Defence Systems and Space Systems - with deep franchises in strategic deterrence, autonomous and crewed aircraft, integrated mission networks, and classified space payloads. The group holds a leading market position in long-cycle, high-barrier US national security programmes and is one of a handful of primes capable of delivering at scale in these domains.
The investment case rests on two near-term hard catalysts: a Q2 2026 earnings print that is expected to extend the recent quarterly beat pattern and reinforce backlog visibility, and continued conversion of the multi-year defence backlog (anchored by programmes such as B-21 Raider, Sentinel, and space systems) into funded revenue through 2027. Backlog conversion underpins the base case; the principal risk is heavy dependence on a single US government customer whose contract modifications, terminations, or budget reprioritisations could materially impair results, as flagged in SEC filings.
Bottom line: BUY. Conviction Score: 74/100. The view would shift to HOLD if there is a clear deceleration in backlog-funded revenue growth or a material adverse modification to a marquee programme such as Sentinel or B-21.
Business Model
Northrop Grumman generates revenue predominantly through long-term, cost-type and fixed-price contracts awarded by the United States government and its allied governments, with the US Department of Defence representing the overwhelmingly dominant customer concentration disclosed in SEC filings. Revenue is recognised over time as work is performed on these contracts, which is typical of the defence prime model and produces relatively predictable cash conversion once a programme is in production. The portfolio is anchored by a small number of very large programmes - including B-21 Raider, the Sentinel intercontinental ballistic missile replacement, the Triton unmanned aircraft system, and a suite of restricted space and missile defence efforts - which together generate a meaningful share of group sales and a multi-year backlog.
The order backlog is the central operating asset of the business. Backlog provides multi-year revenue visibility and underpins margin planning, capacity investment, and supplier commitments. Reported Q1 2026 net sales were USD 9.88 billion, a year-on-year increase of approximately 4.4%, consistent with the modest, programme-driven growth profile of large US defence primes. Contract mix between cost-type (lower margin but lower execution risk) and fixed-price (higher margin but with greater cost-overrun exposure) is a key swing factor in segment margin from year to year and is disclosed in periodic SEC filings.
The competitive moat is structural rather than commercial: high programme switching costs, decades-long incumbency on classified platforms, security clearances, and a US industrial base policy environment that favours existing primes. Competitive risks come principally from the other large US primes (Lockheed Martin, RTX, Boeing Defence, General Dynamics) on overlapping programmes, and from internal execution risk on fixed-price development contracts. Customer concentration with a single US government end-customer is simultaneously the moat and the principal risk, and is disclosed as such in SEC filings.
Financial Snapshot
Recent Catalysts
[21 April 2026] - Northrop Grumman filed its most recent Form 10-Q with the SEC, providing quarterly financial disclosure that includes backlog, segment revenue, and margin commentary underpinning the current thesis. Source: SEC EDGAR / Northrop Grumman Investor Relations.
[14 April 2026] - The company released an earnings announcement and supporting webcast, presentation and transcript materials via its Investor Relations site, framing the quarterly results and outlook. Source: Northrop Grumman Investor Relations.
[13 April 2026] - A further IR disclosure was published on the company Investor Relations feed, providing additional context around the quarterly reporting cycle. Source: Northrop Grumman Investor Relations.
[1 May 2026] - Northrop Grumman announced its 2026 Supplier Excellence Awards, recognising more than 30 domestic suppliers and reinforcing the industrial base underpinning its backlog execution. Source: Northrop Grumman newsroom.
[4 May 2026] - Director Mark A. Welsh III sold 95 shares of NOC, disclosed via insider transaction reporting. Source: Public insider transaction filing.
[Q2 2026 earnings] - The next scheduled earnings release is the Q2 2026 print; the date is unconfirmed in the supplied research data. Source: Northrop Grumman Investor Relations earnings calendar.
Thesis Evaluation
Bull Case (43% weight)
Backlog-funded revenue accelerates into 2027 as B-21 Raider low-rate initial production and Sentinel ground and flight hardware milestones convert into recognised sales, segment margins on fixed-price production lots normalise higher, and free cash flow conversion supports capital return. Sentiment around US defence funding remains constructive through the budget cycle. $680 over a 12-month horizon.
Base Case (49% weight)
Backlog conversion proceeds at the recent low-single-digit revenue growth pace, Q2 2026 delivers an in-line-to-modest beat, and segment margins hold within the disclosed range. Valuation at a P/E of roughly 17x supports a steady total-return outcome. $590 over a 12-month horizon.
Bear Case (8% weight)
A material modification, stretch, or cancellation risk crystallises on a marquee programme such as Sentinel or B-21, or US defence topline is reprioritised under budget pressure, causing backlog-funded revenue growth to stall and segment margins to compress on fixed-price execution. $460 over a 12-month horizon.
Key Risks
- Single-customer US government concentration: The vast majority of revenue is ultimately derived from a single US government end-customer, leaving results exposed to termination, modification, or budget reprioritisation. Estimated probability: 30%. Impact: severe.
- Fixed-price contract cost overruns: Fixed-price development and production lots carry execution risk; cost growth on programmes such as Sentinel has been publicly discussed and could compress segment margins. Estimated probability: 25%. Impact: severe.
- Programme schedule and milestone risk: Large classified and development programmes can experience schedule slips that push revenue and margin recognition into later periods and affect investor sentiment. Estimated probability: 35%. Impact: moderate.
- US defence budget and political cycle risk: Continuing resolutions, sequestration, or shifts in administration priorities could delay obligations and disrupt the cadence of funded backlog conversion. Estimated probability: 40%. Impact: moderate.
- Supply chain and industrial base constraints: Supplier delivery delays, capacity constraints, or skilled-labour shortages could limit the rate at which backlog is converted into recognised revenue. Estimated probability: 30%. Impact: moderate.
- Insider selling signal: Recent director share sales, while small in absolute size, can be read negatively by the market if the pattern persists. Estimated probability: 20%. Impact: low.
Who Should Own It / Avoid It
Ideal for: Long-term, defence-sector-tolerant investors with a minimum holding period of three to five years, moderate-to-low risk tolerance, and a willingness to accept single-customer concentration risk in exchange for backlog visibility and exposure to US national security funding. The position suits a core/defensive allocation within an industrials or defence sleeve rather than a tactical trade.
Avoid if: Investors with a short time horizon, a low tolerance for government-procurement and political-cycle volatility, or a mandate that prohibits single-customer concentration. Those seeking rapid growth or capital-light technology exposure should also look elsewhere, as Northrop Grumman's revenue trajectory is programme-driven and capital-intensive.
Recommendation
BUY - 74/100. The recommendation reflects hard near-term catalysts in the form of the Q2 2026 earnings cycle and continued defence backlog conversion, set against the disclosed single-customer concentration risk. The call would upgrade to a higher conviction tier on clear evidence of accelerating backlog-funded revenue growth, an upward revision to free cash flow guidance, or resolution of fixed-price execution risk on a marquee programme. It would degrade to HOLD on a material adverse programme modification, a multi-quarter slowdown in backlog-funded revenue, or a sustained derating of US defence peer multiples. At the current price of $542.48 the shares trade above our buy ceiling of $503.33: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is $618.30, 14% above the current price of $542.48 - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $503.33 - below this level the upside to the base-case target ($590.00) is at least 2x the downside to the bear case ($460.00), the minimum risk/reward we require before committing new capital.
between $503.33 and $590.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $590.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 43%.
if A material adverse modification, cancellation, or sustained cost-growth event on a marquee programme such as Sentinel or B-21 that materially impairs the backlog-funded revenue trajectory through 2027, regardless of price - the bear target of $460.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 74/100. Trend versus prior report: Down.
| Report date | Conviction |
|---|---|
| 2026-08-01 | 29 |
| 2026-07-25 | 64 |
| 2026-06-13 | 74 |
| 2026-05-30 | 81 |
| 2026-04-27 | 81 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow, company earnings announcements and presentations, regulatory filings, investor relations materials, and third-party financial news wires covering Northrop Grumman's quarterly results, insider transactions, supplier awards, and analyst earnings estimate revisions.
Primary source types: SEC filings (Form 10-Q and Form 8-K on EDGAR), company press releases, company investor relations materials including earnings call transcripts and presentations, regulatory announcements, and third-party financial news coverage.
Key sources
- Northrop Grumman (NOC) Earnings Date and Reports 2026 $NOC
- Northrop Grumman (NOC) Earnings: Latest Report, Earnings Call & Financials
- Northrop Grumman (NOC) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026
- Northrop Grumman (NOC) Stock Forecast and Price Target 2026 $NOC
- News Releases | Northrop Grumman
- Northrop Grumman Corporation (NOC) Stock Price, News, Quote & ...
- Northrop Grumman (NOC) Research Report
- Northrop Grumman Corporation (NOC) Stock Analysis & Key Metrics (2026)
- Quarterly & Annual Financial Results as of Jun, 2026
- Northrop Grumman (NOC) Stock Forecast & Analyst Price Targets
Data correct as of 2026-08-01.